You don't have permission to access "http://www.medpagetoday.com/urology/erectiledysfunction/120747" on this server. Reference #18.afbbce17.1775876540.2a4d4174 https://errors.edgesuite.net/18.afbbce17.1775876540.2a4d4174
You don't have permission to access "http://www.medpagetoday.com/psychiatry/generalpsychiatry/119238" on this server. Reference #18.61f4d517.1767207708.1d1c834a https://errors.edgesuite.net/18.61f4d517.1767207708.1d1c834a
Share on PinterestA recent study concludes that a common type of drug might accelerate cognitive decline.Anticholinergic drugs block the action of acetylcholine, a chemical messenger that controls a range of automatic bodily functions and plays a vital role in memory and attention.Doctors prescribe these drugs for a variety of conditions, including urinary incontinence, overactive bladder,…
Two coronavirus drugs used in cats might help humans infected with the novel coronavirus, according to a preliminary study recently published in the journal Nature.The drugs, dipeptide-based protein inhibitors, referred to as GC376 and GC373, are designed to treat cats with feline infectious peritonitis, a potentially fatal illness caused by another type of coronavirus, feline enteric coronavirus (FCoV), according…
Share on PinterestA multi-institutional team of researchers has pinpointed 13 drugs that they argue could be effective against COVID-19. This finding forms the basis of further treatment trials.The discovery of drugs that may be effective at inhibiting the spread of SARS-CoV-2 has spurred researchers at Yale University in New Haven, CT, to trial a new…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f